The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.
Digital pharma industry news site, Outsourcing-Pharma, spoke with Noxopharm CEO and Managing-Director, Dr Gisela Mautner about Veyonda®’s recent Orphan Drug Designation as a treatment for soft-tissue sarcoma.
Australian biotech news site, Biotech Dispatch reported: US FDA grants new orphan designation to Noxopharm's Veyonda - Biotech
Digital news site, Yahoo! Posted the following: Sarcoma trial cancer treatment begins at City of Hope in Los Angeles.
Global business digital news site, Bloomberg, published the announcement regarding the commencement of Noxopharm’s new sarcoma trial.
US clinical trial news site, Bioworld’s ‘In the Clinic for March 8-14 2022’ noted Noxopharm’s CEP2 trial initiation.
Pharmaceutical news and industry site, Pharmiweb, provided this update on Noxopharm’s new sarcoma trial underway in the US.
Life Sciences industry digital hub, BioSpace, reported “Sarcoma Trial for New Cancer Treatment Begins at City Of Hope (Hospital) in Los Angeles.
The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.Read More
The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.Read More
Which of the following group do you best fit?
Subscribe to our Email Alerts
Subscribe to our Emails and Newsletters